<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    electroCore, Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About electroCore, Inc.

    electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s current indications are for the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $426,000,000
    • SIC CODE
      3845
    • NIN CODE
      ####
    • LEADERSHIP
      Francis R. Amato
    • FOUNDED
      2005
    • EMPLOYEES
      51-100
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Sabra Health Care REIT, Inc.

    Sabra Health Care REIT, Inc.

    As of June 30, 2019, Sabra’s investment portfolio included 432 real estate prope...

    As of June 30, 2019, Sabra’s investment portf...

    Filing Type:    PU
    Angle PLC

    Angle PLC

    ANGLE is a world leading liquid biopsy company with pioneering products in cancer ...

    ANGLE is a world leading liquid biopsy company ...

    Amount Raised:    $250,000
    Fundraising Status:    VT
    Filing Type:    PU
    WayBetter, Inc

    WayBetter, Inc

    WayBetter helps motivate people to adopt healthy behaviors through a combination o...

    WayBetter helps motivate people to adopt health...

    Filing Type:    RARD
    H & G Science, Inc.

    H & G Science, Inc.

    H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...

    H&G Science aims to facilitate the safe and eff...

    Amount Raised:    $24,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    Coherus BioSciences, Inc.

    Coherus BioSciences, Inc.

    Coherus BioSciences is a leading biosimilar company that develops and commercializ...

    Coherus BioSciences is a leading biosimilar com...

    Filing Type:    PU
    Biolase, Inc.

    Biolase, Inc.

    BIOLASE, Inc. is a medical device company and global market leader in the manufact...

    BIOLASE, Inc. is a medical device company and g...

    Filing Type:    PU
    Avenue Therapeutics, Inc.

    Avenue Therapeutics, Inc.

    Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...

    Avenue Therapeutics, Inc., a Fortress Biotech (...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Mesoblast Limited

    Mesoblast Limited

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...

    Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...

    Filing Type:    PU
    BioDelivery Sciences International, Inc.

    BioDelivery Sciences International, Inc.

    BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...

    BioDelivery Sciences International, Inc. (NASDA...

    Filing Type:    PU
    Chiasma, Inc.

    Chiasma, Inc.

    Chiasma is focused on improving the lives of patients who face challenges associat...

    Chiasma is focused on improving the lives of pa...

    Filing Type:    PU
    CymaBay Therapeutics Inc.

    CymaBay Therapeutics Inc.

    We are a clinical-stage biopharmaceutical company focused on developing and provid...

    We are a clinical-stage biopharmaceutical compa...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.